Ribonucleoside Diphosphate Reductase
"Ribonucleoside Diphosphate Reductase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the formation of 2'-deoxyribonucleotides from the corresponding ribonucleotides using NADPH as the ultimate electron donor. The deoxyribonucleoside diphosphates are used in DNA synthesis. (From Dorland, 27th ed) EC 1.17.4.1.
| Descriptor ID |
D012262
|
| MeSH Number(s) |
D08.811.682.810.567
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribonucleoside Diphosphate Reductase".
Below are MeSH descriptors whose meaning is more specific than "Ribonucleoside Diphosphate Reductase".
This graph shows the total number of publications written about "Ribonucleoside Diphosphate Reductase" by people in this website by year, and whether "Ribonucleoside Diphosphate Reductase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribonucleoside Diphosphate Reductase" by people in Profiles.
-
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Mol Oncol. 2020 08; 14(8):1881-1897.
-
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 07 15; 25(14):4480-4492.
-
Quantitative proteomics of the yeast Hsp70/Hsp90 interactomes during DNA damage reveal chaperone-dependent regulation of ribonucleotide reductase. J Proteomics. 2015 Jan 01; 112:285-300.
-
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
-
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol. 2011 Feb; 131(2):453-60.